To estimate this period, we retrospectively evaluated the efficacy of PD-1/PD-L1 inhibitors after the discontinuation of these antibodies due to AEs in patients with NSCLC at Japanese cancer research institutes. The gene discussed is CD274; the disease is non-small cell lung carcinoma.